Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
NA The study was prematurely discontinued due to slow enrollment and keeping in mind the observational nature of the study. The decision to terminate had been taken on 16th June 2012 and the LSLV occured on 14th September, 2012. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with early breast cancer receiving adjuvant therapy with Aromasin® will be eligible.
You may not be if
Patients presenting with in situ cancers, recurrent or metastatic breast cancer, or a 2nd primary will not be included.
Patients with a known hypersensitivity to Exemestane or its metabolites will also not be included.
Clareo Health | An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin
